

Program at a Glance

Tuesday, Aug. 31	
Room A	Room B-1
Opening remarks	
8:10 ES01 Educational Session-1 The mesothelial cell	
8:35 ES02 Educational Session-2 Mechanisms of asbestos-induced carcinogenesis	
9:00 ES03 Educational Session-3 Basic research for mesothelioma: apoptosis	
9:25 ES04 Educational Session-4 New pathways for molecular targeted therapies	
9:50 ES05 Educational Session-5 Clinically relevant chromosomal and molecular biomarkers in asbestos-related tumors	
10:15 Break	
10:35 ES06 Educational Session-6 Clinical aspects of malignant pleural mesothelioma	
11:00 ES07 Educational Session-7 Peritoneal Mesothelioma - Clinical and Translational Research in Pharmacology of Cancer Chemotherapy -	
11:25 ES08 Educational Session-8 New aspects in diagnostic tools for mesothelioma	
11:50 LS Lunch Seminar Treatment and prophylaxis of MRSA infections in patients with thoracic malignancy <i>(Co-sponsored by Pfizer Japan Inc.)</i>	
13:00 ES09 Educational Session-9 First- and second-line chemotherapy for mesothelioma	13:00 ES PL01 Educational Session Pathology Lecture-1 Advances in mesothelioma pathology
13:25 ES10 Educational Session-10 Palliative benefit of chemotherapy for mesothelioma	13:40 ES PL02 Pathology Lecture-2 Cytological diagnosis for mesothelioma
13:50 ES11 Educational Session-11 Immunotherapy for mesothelioma	
14:15 ES12 Educational Session-12 Gene therapy for mesothelioma	14:15 Break
14:40 Break	
15:00 ES13 Educational Session-13 TNM staging of malignant pleural mesothelioma	15:00 ES PL03 Pathology Lecture-3 Verification of the consensus statement from the IMIG2006
15:25 ES14 Educational Session-14 Role of radical surgery within a multimodality concept	15:40 ES PL04 Pathology Lecture-4 Mesothelioma with special references to diagnostic accuracy
15:50 ES15 Educational Session-15 Overview of the surgical debate for pleural mesothelioma	
16:15 Break	
16:45 ES16 Educational Session-16 Multimodality approaches for mesothelioma	16:45 DC01 Difficult cases: ask the expert 1. Separation of benign from malignant pleural mesothelioma 2. Rare variant
17:10 ES17 Educational Session-17 European guidelines for the treatment of malignant pleural mesothelioma	
17:35 ES18 Educational Session-18 Trends in mesothelioma incidence	
18:00	

Program at a Glance

Wednesday, Sept. 1				
Room A	Room B-1	Room B-2	Annex 2	Annex 1
8:30 Welcome address President's address 8:40 Introduction to IMIG Web site				
9:00 S01 Epidemiology	S02 Clinical tumor markers: the state of the art	S03 Biology Pathogenesis	RD01 Round-table discussion Pathology-I: new insights	Poster Mounting
10:20 Break				
PD01 Panel discussion Asbestos in the world	S04 Biomarkers	S05 Novel targets	WS01 Workshop Cytopathology -How reliable is it?-	
11:50 12:00			11:50	Poster Viewing
LS01 Special Lunch Seminar-I (Co-sponsored by Merck & Co., Inc.)			LS02 Special Lunch Seminar-II (Co-sponsored by Ono Pharmaceutical Co., Ltd.)	
13:00 S06 First-line treatment	S07 SMRP & MPF	DC02 Pathology-II: Difficult cases: ask the expert	WS02 Workshop Molecular oncogenesis	
	14:00 S08 PET scan in MPM Imaging	S09 Thoracoscopy	14:30	
14:30 S10 Second-line treatment	15:00 S11 Peritoneal mesothelioma	S12 Radiation biology & Radiotherapy-I	WS03 Workshop Tumor microenvironment & Oncogenesis	
16:00 Break				
16:20 S13 Molecular target therapy	WS04 Workshop Peritoneal mesothelioma -Clinical and translational research-	S14 Radiation biology & Radiotherapy-II	S15 Screening	
17:30				

Program at a Glance

Thursday, Sept. 2					Friday, Sept. 3
Room A	Room B-1	Room B-2	Annex 2	Annex 1	Room A
9:00 RD02 Round-table discussion Surgery-I	WS05 Workshop Apoptosis and mesothelioma	S16 Animal models	WS06 Workshop Immunotherapy: bench to bedside-I	Poster viewing	Satellite Symposium
10:30 Break					
10:50 S17 Multimodality treatment	S18 Clinical trials	S19 Prognostic factors	WS07 Workshop Immunotherapy: bench to bedside-II		
LS03 Special Lunch Seminar-III (Co-sponsored by Eli Lilly)			LS04 Special Lunch Seminar-IV (Co-sponsored by Shionogi & Co., Ltd.)		
				13:00 Poster discussion	
14:00 WS08 Workshop Immunotherapy: bench to bedside-III	S20 TNM staging for MPM	S21 Chemotherapy	PD02 Panel discussion Legal aspects	Poster removal	
14:40 SY01 Symposium Carbon nanotubes and other possible causes of mesothelioma	14:50 S22 Surgery-II				
16:00 Poster awards					